Briefing
The European Commission on 15 July 2026 granted marketing authorisation for Wegovy in tablet form (semaglutide 25 mg, once daily) as a weight management treatment in the European Union. The decision followed a positive opinion in May 2026 from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA), which expressly recommended an oral formulation of Wegovy. The medicine is authorised as an adjunct to a reduced-calorie diet and increased physical activity for weight loss and weight maintenance in adults with obesity or overweight plus at least one weight-related comorbidity. (Sources: EMA, Novo Nordisk).
In Spain, Wegovy in tablet form now has a national authorisation or registration entry and is dispensed in pharmacies dispensed; the national database of the Ministerio de Sanidad lists the medicine and identifies Novo Nordisk as the holder. It is dispensed on prescription. Current official entries name the product, its indication and its identification numbers, but also confirm that Wegovy is not currently included on the public reimbursement list (Nomenclátor/funding status). Reimbursement decisions may vary between regions in Spain; there is no nationwide coverage by the National Health System. (Sources: Ministerio de Sanidad / Nomenclátor).
For efficacy and use, the authorisation documents refer to randomised studies in which average weight reductions and responder-dependent maximum effects were reported alongside lifestyle measures; precise figures for averages and safety information are set out in the Summary of Product Characteristics (SmPC), which was updated and published following the European Commission’s decision. Figures for specific price bands in Spain vary between media reports; the relevant official lists and negotiations determine the binding prices and reimbursement conditions.
The key news — EC authorisation of Wegovy as a tablet and its national listing/availability in Spain — is supported by EMA documents and Spanish authority records. The question of public reimbursement and detailed cost information by region remains open.
Editor: Clara Simonichek (Article created with AI assistance).